
When Novo Nordisk entered into an agreement with US company Dicerna two years ago, it had seen the potential in manipulating RNA, like many other players in the industry.
Danish financial daily Børsen reports that the deal concerns a specific form of RNA technology, called RNA interference, or RNAi, which aims to reduce the production of damaging proteins. Karin Conde-Knape, Senior Vice President of Global Drug Discovery at Novo Nordisk, calls the approach "clearly exciting".
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app